What is the recommended empiric therapy for cervicitis while awaiting diagnostic testing, including coverage for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium, and herpes simplex virus, and how should the regimen be modified in pregnancy?

Treatment for Cervicitis

Initiate empiric therapy with azithromycin 1 g orally as a single dose (or doxycycline 100 mg orally twice daily for 7 days) immediately in high-risk patients—those younger than 25 years, with new or multiple sexual partners, reporting unprotected intercourse, or when follow-up is uncertain—while awaiting nucleic acid amplification test (NAAT) results for Chlamydia trachomatis and Neisseria gonorrhoeae. 1

Risk Stratification and Decision to Treat Empirically

Treat immediately without awaiting test results if the patient meets any of these criteria: 2, 1

• Age younger than 25 years
• New or multiple sexual partners
• Unprotected sexual intercourse
• Unreliable follow-up anticipated
• High community prevalence of sexually transmitted infections

In low-risk patients with assured follow-up, you may await NAAT results before initiating therapy. 2

Recommended Empiric Regimens (Non-Pregnant Patients)

First-line therapy: 2, 1

• Azithromycin 1 g orally as a single dose (preferred for directly observed therapy and compliance)
• OR doxycycline 100 mg orally twice daily for 7 days

Both regimens have similar efficacy and toxicity profiles; azithromycin offers the advantage of single-dose administration, while doxycycline has a longer track record and lower cost. 2

When to Add Gonococcal Coverage

Add treatment for N. gonorrhoeae when: 2, 1

• Local gonorrhea prevalence exceeds 5% in your patient population
• The patient belongs to a high-risk setting (STD clinic attendees, young age groups)
• Gram-negative intracellular diplococci are seen on cervical Gram stain (>99% specific for gonorrhea) 1

Current gonococcal regimen: 3

• Ceftriaxone 500 mg intramuscularly as a single dose plus azithromycin 1 g orally (dual therapy is mandatory due to high rates of chlamydial co-infection)

Management of Concurrent Infections

Test for and treat the following when identified: 2, 1

• Trichomoniasis: Metronidazole 2 g orally as a single dose 1
• Bacterial vaginosis: Treat if symptomatic 2, 1
• Mycoplasma genitalium: If NAAT is available and positive, use azithromycin 500 mg on day 1, then 250 mg daily on days 2–5; for macrolide resistance or treatment failure, use moxifloxacin 400 mg orally daily for 7 days 4

Critical pitfall: Wet-mount microscopy misses Trichomonas vaginalis in 30–50% of cases; if clinical suspicion persists despite negative microscopy, order NAAT for trichomoniasis. 1

Essential Diagnostic Testing

Obtain the following tests before or concurrent with empiric treatment: 2, 1

• NAATs for C. trachomatis and N. gonorrhoeae (cervical or urine specimens; markedly superior to microscopy with sensitivities 86–100% and specificities 97–100%) 1, 3
• Wet-mount microscopy of vaginal secretions to assess for ≥10 WBC per high-power field and detect Trichomonas vaginalis 1
• Bacterial vaginosis testing 1
• Syphilis serology and HIV testing for every patient with a new STI diagnosis 1

Do not rely on Gram stain alone: Endocervical Gram stain for gonorrhea has only ~50% sensitivity despite >99% specificity; a negative result cannot exclude infection. 1

Modifications in Pregnancy

Azithromycin 1 g orally as a single dose is the preferred treatment for cervicitis in pregnant women. 5

Doxycycline is absolutely contraindicated in pregnancy. 5

All other management principles remain the same: 5

• Treat empirically in high-risk patients without awaiting results
• Add gonococcal coverage if local prevalence >5%
• Obtain NAATs for C. trachomatis and N. gonorrhoeae
• Test for and treat trichomoniasis and bacterial vaginosis if present
• Perform syphilis and HIV testing

Partner Management Protocol

All sexual partners within the preceding 60 days must be: 2, 1, 5

• Notified and examined
• Treated with the same antimicrobial regimen as the index patient regardless of symptoms or test results
• Instructed to abstain from sexual intercourse for 7 days after single-dose therapy or until completion of 7-day regimens

Failure to treat partners adequately is the primary cause of persistent infection and reinfection. 4

Follow-Up and Management of Persistent Cervicitis

Patients should return for reassessment if: 2, 1

• Symptoms persist after completing therapy
• New symptoms develop

For persistent cervicitis after initial treatment, systematically evaluate: 2, 1

1. Re-exposure to an STD (inadequately treated or new partners)
2. Relapse or reinfection with specific pathogens (repeat NAATs)
3. Vaginal flora abnormalities (bacterial vaginosis)
4. Partner treatment status (verify all partners were evaluated and treated)

If no pathogen is identified after appropriate evaluation and partners are treated, consider: 2, 1

• Non-infectious causes: frequent douching, chemical irritants from feminine hygiene products, cervical ectropion 1
• The value of repeated or prolonged antibiotic therapy is unknown and not recommended 1
• Referral to a gynecologic specialist for possible ablative therapy in cases of persistent symptomatic cervicitis 1

Special Populations

HIV-infected patients receive the same treatment regimens as HIV-negative patients. 2, 1 However, prompt treatment is especially important because cervicitis in HIV-infected individuals increases cervical HIV shedding and may enhance transmission to partners. 1

Prevention of Long-Term Sequelae

Immediate administration of appropriate antibiotics directly reduces the risk of: 1

• Pelvic inflammatory disease
• Infertility
• Ectopic pregnancy
• Chronic pelvic pain

Untreated C. trachomatis cervicitis can progress to subclinical upper genital tract infection even in apparently uncomplicated cases. 2 This is why empiric treatment in high-risk patients is critical—delaying therapy while awaiting test results increases the risk of progression to PID and its complications. 1

Common Pitfalls to Avoid

• Do not withhold treatment in high-risk patients while awaiting test results—the risk of progression to PID outweighs the risk of unnecessary antibiotics 1
• Do not use doxycycline in pregnant women 5
• Do not forget partner treatment—reinfection rates are substantially higher when partners are not adequately treated 1, 4
• Do not continue empiric antibiotics indefinitely for persistent cervicitis without an identified pathogen—this has no proven benefit 1
• Do not assume a negative wet mount excludes trichomoniasis—order NAAT if clinical suspicion persists 1